Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry.
暂无分享,去创建一个
J. McMurray | L. Lund | P. Jhund | M. Petrie | U. Dahlström | G. Savarese | A. Jackson | L. Benson | C. Hage
[1] P. Ponikowski,et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. , 2006, European heart journal.
[2] R. Touyz,et al. Adipocytes Produce Aldosterone Through Calcineurin-Dependent Signaling Pathways: Implications in Diabetes Mellitus–Associated Obesity and Vascular Dysfunction , 2012, Hypertension.
[3] Akshay S. Desai,et al. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. , 2017, JACC. Heart failure.
[4] S. Solomon,et al. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction , 2018, American journal of hypertension.
[5] M. Banach,et al. Leptin, cardiovascular diseases and type 2 diabetes mellitus , 2018, Acta Pharmacologica Sinica.
[6] L. Lund,et al. The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure , 2018, Upsala journal of medical sciences.
[7] C. Fava,et al. Prevalence and Comorbidities of Resistant Hypertension: A Collaborative Population-Based Observational Study , 2018, High Blood Pressure & Cardiovascular Prevention.
[8] C. Thakar,et al. Adherence to Antihypertensive Agents and Blood Pressure Control in Chronic Kidney Disease , 2010, American Journal of Nephrology.
[9] L. Weinrauch,et al. MICROVASCULAR COMPLICATIONS — NEPHROPATHY ( B ROSHAN , 2014 .
[10] Nancy M Albert,et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. , 2006, JAMA.
[11] David A Calhoun,et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. , 2018, Hypertension.
[12] Thomas Kahan,et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.
[13] U. Dahlström,et al. Heart failure registry: a valuable tool for improving the management of patients with heart failure , 2010, European journal of heart failure.
[14] P. Ponikowski,et al. [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.
[15] L. Ruilope,et al. Resistant hypertension: new insights and therapeutic perspectives. , 2019, European heart journal. Cardiovascular pharmacotherapy.
[16] L. Igel,et al. Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment , 2013, Journal of clinical hypertension.
[17] H. Ross,et al. Prognostic value of blood pressure in ambulatory heart failure: a meta-analysis and systematic review. Ambulatory blood pressure predicts heart failure prognosis , 2021, Heart Failure Reviews.
[18] D. Kitzman,et al. The pathogenesis of acute pulmonary edema associated with hypertension. , 2001, The New England journal of medicine.
[19] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[20] T. Cascino,et al. Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction , 2017, Current Hypertension Reports.
[21] T. Tsujimoto,et al. Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension , 2020, Journal of the American Heart Association.
[22] C. Yancy,et al. Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction , 2018, JAMA cardiology.
[23] Heather M. Tavel,et al. Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients , 2012, Circulation.
[24] J. Sun,et al. The Prevalence and Prognosis of Resistant Hypertension in Patients with Heart Failure , 2014, PloS one.
[25] J. Lima,et al. Early Onset Hypertension Is Associated With Hypertensive End-Organ Damage Already by MidLife. , 2019, Hypertension.
[26] B. Davis,et al. Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease: Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 2014, Hypertension.
[27] Takeshi Kimura,et al. Admission systolic blood pressure as a prognostic predictor of acute decompensated heart failure: A report from the KCHF registry , 2021, PloS one.
[28] Isla Mackenzie,et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial , 2015, The Lancet.
[29] S. Solomon,et al. Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction , 2021, European heart journal.
[30] G. Russo,et al. Resistant Hypertension, Time‐Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus , 2017, Journal of the American Heart Association.
[31] L. Lund,et al. Heart failure with mid-range or mildly reduced ejection fraction , 2021, Nature Reviews Cardiology.